Brennan DJ - Search Results

1

Interleukin-6 as a therapeutic target in human ovarian cancer.

Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, Singh N, Avril N, Cummings J, Rexhepaj E, Jirström K, Gallagher WM, Brennan DJ, McNeish IA, Balkwill FR. Coward J, et al. Among authors: brennan dj. Clin Cancer Res. 2011 Sep 15;17(18):6083-96. doi: 10.1158/1078-0432.CCR-11-0945. Epub 2011 Jul 27. Clin Cancer Res. 2011. PMID: 21795409 Free PMC article. Clinical Trial.

2

Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response.

Brennan DJ, O'Brien SL, Fagan A, Culhane AC, Higgins DG, Duffy MJ, Gallagher WM. Brennan DJ, et al. Expert Opin Biol Ther. 2005 Aug;5(8):1069-83. doi: 10.1517/14712598.5.8.1069. Expert Opin Biol Ther. 2005. PMID: 16050784 Review.

3

CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.

Brennan DJ, Jirstrom K, Kronblad A, Millikan RC, Landberg G, Duffy MJ, Rydén L, Gallagher WM, O'Brien SL. Brennan DJ, et al. Clin Cancer Res. 2006 Nov 1;12(21):6421-31. doi: 10.1158/1078-0432.CCR-06-0480. Clin Cancer Res. 2006. PMID: 17085655 Clinical Trial.

4

CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer.

O'Brien SL, Fagan A, Fox EJ, Millikan RC, Culhane AC, Brennan DJ, McCann AH, Hegarty S, Moyna S, Duffy MJ, Higgins DG, Jirström K, Landberg G, Gallagher WM. O'Brien SL, et al. Among authors: brennan dj. Int J Cancer. 2007 Apr 1;120(7):1434-43. doi: 10.1002/ijc.22413. Int J Cancer. 2007. PMID: 17205517 Free PMC article.

5

Breast cancer proteomics: clinical perspectives.

Lau TY, O'Connor DP, Brennan DJ, Duffy MJ, Pennington SR, Gallagher WM. Lau TY, et al. Among authors: brennan dj. Expert Opin Biol Ther. 2007 Feb;7(2):209-19. doi: 10.1517/14712598.7.2.209. Expert Opin Biol Ther. 2007. PMID: 17250459 Review.

6

Survivin: a promising tumor biomarker.

Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Duffy MJ, et al. Among authors: brennan dj. Cancer Lett. 2007 Apr 28;249(1):49-60. doi: 10.1016/j.canlet.2006.12.020. Epub 2007 Feb 1. Cancer Lett. 2007. PMID: 17275177 Review.

7

Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer.

Brennan DJ, Kelly C, Rexhepaj E, Dervan PA, Duffy MJ, Gallagher WM. Brennan DJ, et al. Cancer Genomics Proteomics. 2007 May-Jun;4(3):121-34. Cancer Genomics Proteomics. 2007. PMID: 17878516 Free article. Review.

8

Prognostic ability of a panel of immunohistochemistry markers - retailoring of an 'old solution'.

Brennan DJ, Gallagher WM. Brennan DJ, et al. Breast Cancer Res. 2008;10(1):102. doi: 10.1186/bcr1854. Epub 2008 Feb 25. Breast Cancer Res. 2008. PMID: 18331621 Free PMC article.

9

Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer.

Brennan DJ, Rexhepaj E, O'Brien SL, McSherry E, O'Connor DP, Fagan A, Culhane AC, Higgins DG, Jirstrom K, Millikan RC, Landberg G, Duffy MJ, Hewitt SM, Gallagher WM. Brennan DJ, et al. Clin Cancer Res. 2008 May 1;14(9):2681-9. doi: 10.1158/1078-0432.CCR-07-1760. Clin Cancer Res. 2008. PMID: 18451232 Free PMC article.

10

Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.

Borgquist S, Jögi A, Pontén F, Rydén L, Brennan DJ, Jirström K. Borgquist S, et al. Among authors: brennan dj. Breast Cancer Res. 2008;10(5):R79. doi: 10.1186/bcr2146. Epub 2008 Sep 22. Breast Cancer Res. 2008. PMID: 18808688 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

196 results

Search Page